Zeynep Eroglu

10.7k total citations · 1 hit paper
124 papers, 3.7k citations indexed

About

Zeynep Eroglu is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Zeynep Eroglu has authored 124 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 54 papers in Molecular Biology and 32 papers in Immunology. Recurrent topics in Zeynep Eroglu's work include Cancer Immunotherapy and Biomarkers (47 papers), CAR-T cell therapy research (43 papers) and Melanoma and MAPK Pathways (39 papers). Zeynep Eroglu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (47 papers), CAR-T cell therapy research (43 papers) and Melanoma and MAPK Pathways (39 papers). Zeynep Eroglu collaborates with scholars based in United States, Australia and Germany. Zeynep Eroglu's co-authors include Antoni Ribas, Douglas B. Johnson, Alexander N. Shoushtari, Georgina V. Long, Ryan J. Sullivan, Jeffrey A. Sosman, Alexander M. Menzies, Katy K. Tsai, Vernon K. Sondak and Jonathan S. Zager and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Zeynep Eroglu

114 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Alexander M. Menzies, Douglas B. Johnson et al. profile →

Peers

Countries citing papers authored by Zeynep Eroglu

Since Specialization

Citations

This map shows the geographic impact of Zeynep Eroglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeynep Eroglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeynep Eroglu more than expected).

Fields of papers citing papers by Zeynep Eroglu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeynep Eroglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeynep Eroglu. The network helps show where Zeynep Eroglu may publish in the future.

Co-authorship network of co-authors of Zeynep Eroglu

This figure shows the co-authorship network connecting the top 25 collaborators of Zeynep Eroglu. A scholar is included among the top collaborators of Zeynep Eroglu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeynep Eroglu. Zeynep Eroglu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B 2025 ·Clinical Cancer Research ·Diwakar Davar, Zeynep Eroglu, Mohammed Milhem, Carlos Becerra, Martin Gutierrez, Antoni Ribas, (unknown), (unknown), Hailei Zhang, (unknown), (unknown), (unknown), Shyam Srivats, (unknown), Arindam Dhar, Patricia LoRusso	1
2	Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A 2025 ·Clinical Cancer Research ·Diwakar Davar, Zeynep Eroglu, (unknown), (unknown), (unknown), Niranjan Yanamandra, (unknown), Kathrin Jansen, Arindam Dhar, (unknown), (unknown), Antoni Ribas	2
3	Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A. Tarhini, Evan Wuthrick, Vernon K. Sondak, Nikhil I. Khushalani, Kenneth Y. Tsai, Andrew S. Brohl	5
4	Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy 2024 ·Cancer Medicine ·Aasha I. Hoogland, Andrew S. Brohl, Brent J. Small, (unknown), Evan Wuthrick, Zeynep Eroglu, Dukagjin Blakaj, Claire F. Verschraegen, Nikhil I. Khushalani, Heather Jim, Sungjune Kim	2
5	Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC). 2024 ·Journal of Clinical Oncology ·Andrew S. Brohl, Ann W. Silk, Jacob Thomas, Zeynep Eroglu, Ahmad A. Tarhini, (unknown), (unknown), Nikhil I. Khushalani, Joseph Markowitz, Kenneth Y. Tsai	1
6	Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A. Tarhini, Evan Wuthrick, Vernon K. Sondak, Nikhil I. Khushalani, Kenneth Y. Tsai, Andrew S. Brohl	0
7	First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0 2024 ·Molecular Cancer Therapeutics ·Joseph Markowitz, Michael J. Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani, (unknown), (unknown), (unknown), (unknown), (unknown), Pei-Ling Chen, (unknown), Vernon K. Sondak, Ahmad A. Tarhini, Youngchul Kim, (unknown), Shari Pilon‐Thomas	5
8	Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma 2024 ·Clinical Cancer Research ·Ahmad A. Tarhini, Zeynep Eroglu, (unknown), Jonathan S. Zager, R. Gonzalez, Amod A. Sarnaik, (unknown), Nikhil I. Khushalani, (unknown), (unknown), (unknown), Allison Richards, Michael J. Schell, (unknown), Pei-Ling Chen, Jane L. Messina, David A. Canton, Vernon K. Sondak	4
9	Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients 2023 ·Cancer ·Zeynep Eroglu, (unknown), Ekaterina Kalashnikova, (unknown), (unknown), (unknown), (unknown), (unknown), Charuta C. Palsuledesai, Meenakshi Malhotra, (unknown), Joseph Markowitz, Nikhil I. Khushalani, Ahmad A. Tarhini, Jane L. Messina, Alexey Aleshin	33
10	Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma 2023 ·Cancers ·Julian A. Marin‐Acevedo, (unknown), Youngchul Kim, Andrew S. Brohl, Zeynep Eroglu, Joseph Markowitz, Ahmad A. Tarhini, Kenneth Y. Tsai, Nikhil I. Khushalani	14
11	Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma 2023 ·Cancer ·Zeynep Eroglu, Y. Ann Chen, Inna Smalley, Jiannong Li, Joseph Markowitz, Andrew S. Brohl, Leticia Tetteh, (unknown), Vernon K. Sondak, Nikhil I. Khushalani, Keiran S.M. Smalley	9
12	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases 2021 ·Clinical Cancer Research ·Inna Smalley, Zhihua Chen, Manali Phadke, Jiannong Li, Xiaoqing Yu, (unknown), Brittany Evernden, Jane L. Messina, Amod A. Sarnaik, Vernon K. Sondak, Chaomei Zhang, Vincent Law, Nam Tran, Arnold B. Etame, Robert Macaulay, Zeynep Eroglu, Peter Forsyth, Paulo C. Rodrı́guez, Y. Ann Chen, Keiran S.M. Smalley	96
13	Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity 2021 ·Cancer Immunology Research ·(unknown), Zhihua Chen, Jiannong Li, Eslam Mohamed, Michael A. Davies, Inna Smalley, Derek R. Duckett, Vinayak Palve, Brian J. Czerniecki, Peter Forsyth, David Noyes, Dennis O. Adeegbe, Zeynep Eroglu, (unknown), Kenneth Y. Tsai, Uwe Rix, Christin E. Burd, Y. Ann Chen, Paulo C. Rodrı́guez, Keiran S.M. Smalley	19
14	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy 2021 ·European Journal of Cancer ·Helen Clare Dearden, Lewis Au, Daniel Wang, Lisa Zimmer, Zeynep Eroglu, Jessica L. Smith, (unknown), Chloe Khoo, Victoria Atkinson, Serigne Lo, Georgina V. Long, Shahneen Sandhu, Paolo A. Ascierto, Matteo S. Carlino, Douglas B. Johnson, James Larkin, Alexander M. Menzies	24
15	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma 2021 ·Journal of Clinical Oncology ·Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario R. Velasco, Jose Lutzky, Emily F. Higgs, Riyue Bao, Timothy Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil I. Khushalani, Jason J. Luke	136
16	Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients 2019 ·Cancer Immunology Research ·Douglas B. Johnson, (unknown), Justine V. Cohen, (unknown), Alexandra M. Haugh, Daniel Wang, (unknown), (unknown), Kenneth L. Gage, Florian J. Fintelmann, Ryan J. Sullivan, Zeynep Eroglu, Richard G. Abramson	20
17	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy 2019 ·Clinical Cancer Research ·Todd C. Knepper, Meagan Montesion, Jeffery S. Russell, Ethan S. Sokol, Garrett M. Frampton, Vincent A. Miller, Lee A. Albacker, Howard L. McLeod, Zeynep Eroglu, Nikhil I. Khushalani, Vernon K. Sondak, Jane L. Messina, Michael J. Schell, James A. DeCaprio, Kenneth Y. Tsai, Andrew S. Brohl	111
18	Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma 2017 ·Cancer Immunology Research ·Daniel Wang, Zeynep Eroglu, Alpaslan Özgün, Paul Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard W. Joseph, Rizwan Haq, Patrick A. Ott, F. Stephen Hodi, Jeffrey A. Sosman, Douglas B. Johnson, Elizabeth I. Buchbinder	35
19	Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines 2017 ·Molecular Cancer Therapeutics ·Daniel Verduzco, Brent M. Kuenzi, Fumi Kinose, Vernon K. Sondak, Zeynep Eroglu, Uwe Rix, Keiran S.M. Smalley	13
20	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy 2015 ·Therapeutic Advances in Medical Oncology ·Zeynep Eroglu, Antoni Ribas	220

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact